Vaccine against malaria could be ready in 5 years

Sanofi-aventis has announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid (PUA) levels compared to allopurinol

Full Post: Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome.

Malaria is caused by Plasmodium falciparum, the most deadly malaria parasite transmitted by the female anopheles mosquito and is the leading killer of children under the age of five in sub-Saharan Africa.

Trials of the experimental vaccine have shown that it provides significant protection for infants and young children - the vaccine currently known by its codename RTS,S, is the most promising vaccine yet to result from 20 years of research and has already been seen to be effective protecting adults and babies in the Gambia and Mozambique against malaria.

The RTS,S vaccine candidate is a recombinant protein that fuses a part of the Plasmodium falciparum circumsporozoite protein with the hepatitis B surface antigen molecule. Combined with a proprietary GSK adjuvant system, RTS,S induces the production of antibodies and white blood cells that are believed to diminish the capacity of the malaria parasite to infect, survive, and develop in the human liver. In addition to inducing partial protection against malaria, the RTS,S vaccine candidate stimulates a protective immune response to hepatitis B, a common infection in developing countries.

The latest trials carried out in Kenya and Tanzania, have shown for the first time that the vaccine can be given as part of the standard immunisation programme as it does not interfere with childhood vaccines against diphtheria, tetanus, whooping cough and meningitis, and still provides protection.

Scientists say this will make delivery of the vaccine much easier and less costly in Africa and if regulatory approval can be obtained, a final trial involving thousands of African children is planned for next year.

The vaccine has raised hopes of an effective weapon against one of the world’s biggest killers as there are as many as 500 million malaria infections every year, mostly in the developing world.

The Tanzanian trial involving 340 infants and showed the vaccine reduced malaria infections over six months by up to 65% in babies under one year, who are the most vulnerable.

Each infant received three doses at eight, 12 and 16 weeks and in a separate trial involving almost 900 older children in Kenya and Tanzania, aged five to 17 months, a slightly different version of the same vaccine reduced cases of malaria requiring hospital treatment by 53%.

The RTS,S candidate malaria vaccine was created in 1987. Its early development was undertaken by GlaxoSmithKline (GSK) Biologicals, the vaccine division of GSK, in close collaboration with the Walter Reed Army Institute of Research (WRAIR). In January 2001, GSK and the PATH Malaria Vaccine Initiative (MVI) - with support from the Bill & Melinda Gates Foundation - entered into an agreement to develop the vaccine for children in sub­Saharan Africa

The results were presented this week at the annual meeting of the American Society for Tropical Medicine and Hygiene in New Orleans and are published in The New England Journal of Medicine.


Experts are recommending that a malaria vaccine progress to Phase 3 trials following the successful trial of the RTS, S/AS01E malaria vaccine among 5-17 month old children in Korogwe, Tanzania and coastal Kenya, which is reported in the New England Journal of Medicine (NEJM). In a separate paper, which also appears in the online journal,

Full Post: Promising trials of malaria vaccine in East Africa lead to calls for phase 3 development

All countries should offer universal infant immunization for hepatitis B, write Dr. Christopher Mackie from McMaster University and coauthors in a public health analysis in CMAJ. Epidemiological studies suggest that roughly one-third of chronic hepatitis B infections are acquired during infancy and early childhood. In Canada, British Columbia, New Brunswick and Prince Edward Island are

Full Post: All countries should offer universal infant immunization for hepatitis B

A new debate in the open access journal PLoS Medicine questions whether all African children with fever should be treated presumptively with antimalarial drugs, or if treatment should wait until laboratory tests confirm malarial infection. Blaise Genton and colleagues from Tanzania contend that declining malarial transmission rates in parts of sub-Saharan Africa and the availability

Full Post: Debate on treating fevers in African children

The results of two new large scale trials show that the combination of dihydroartemisinin and piperaquine (DHA+PQP) not only is effective against uncomplicated malaria in a way which is comparable to other artemisinin-based combination therapies (ACTs), but it also protects patients against new infections for at least two months after treatment. The DHA/PQP combination is

Full Post: Combo malaria treatment dihydroartemisinin and piperaquine shows promise

The use of insecticide-treated bed nets (ITNs) to protect children from malaria has risen six-fold in the past seven years, according to research funded by the Wellcome Trust. Despite this success, however, 90 million children still do not have access to this simple protective tool, and remain at risk from the life-threatening disease. Malaria kills

Full Post: Use of insecticide-treated bed nets increases, but 90 million African children still exposed to malaria